Literature DB >> 27761021

Clinical trials: The rise of IL-2 therapy - a novel biologic treatment for SLE.

Jens Y Humrich1, Gabriela Riemekasten1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27761021     DOI： 10.1038/nrrheum.2016.173

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  8 in total

1.  Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE.

Authors:  Jens Y Humrich; Caroline von Spee-Mayer; Elise Siegert; Tobias Alexander; Falk Hiepe; Andreas Radbruch; Gerd-Rüdiger Burmester; Gabriela Riemekasten
Journal:  Ann Rheum Dis       Date:  2015-01-21       Impact factor: 19.103

2.  Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.

Authors:  David Saadoun; Michelle Rosenzwajg; Florence Joly; Adrien Six; Fabrice Carrat; Vincent Thibault; Damien Sene; Patrice Cacoub; David Klatzmann
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

3.  Interleukin-2 and regulatory T cells in graft-versus-host disease.

Authors:  John Koreth; Ken-ichi Matsuoka; Haesook T Kim; Sean M McDonough; Bhavjot Bindra; Edwin P Alyea; Philippe Armand; Corey Cutler; Vincent T Ho; Nathaniel S Treister; Don C Bienfang; Sashank Prasad; Dmitrios Tzachanis; Robin M Joyce; David E Avigan; Joseph H Antin; Jerome Ritz; Robert J Soiffer
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

Review 4.  The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases.

Authors:  David Klatzmann; Abul K Abbas
Journal:  Nat Rev Immunol       Date:  2015-04-17       Impact factor: 53.106

5.  Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus.

Authors:  Jens Y Humrich; Henner Morbach; Reinmar Undeutsch; Philipp Enghard; Stefan Rosenberger; Olivia Weigert; Lutz Kloke; Juliane Heimann; Timo Gaber; Susan Brandenburg; Alexander Scheffold; Jochen Huehn; Andreas Radbruch; Gerd-Rüdiger Burmester; Gabriela Riemekasten
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

6.  Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.

Authors:  Caroline von Spee-Mayer; Elise Siegert; Dimas Abdirama; Angelika Rose; Anika Klaus; Tobias Alexander; Philipp Enghard; Birgit Sawitzki; Falk Hiepe; Andreas Radbruch; Gerd-Rüdiger Burmester; Gabriela Riemekasten; Jens Y Humrich
Journal:  Ann Rheum Dis       Date:  2015-08-31       Impact factor: 19.103

7.  Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.

Authors:  Jing He; Xia Zhang; Yunbo Wei; Xiaolin Sun; Yaping Chen; Jun Deng; Yuebo Jin; Yuzhou Gan; Xin Hu; Rulin Jia; Chuanhui Xu; Zhaohua Hou; Yew Ann Leong; Lei Zhu; Jinhong Feng; Yuan An; Yuan Jia; Chun Li; Xu Liu; Hua Ye; Limin Ren; Ru Li; Haihong Yao; Yuhui Li; Shi Chen; Xuewu Zhang; Yin Su; Jianping Guo; Nan Shen; Eric F Morand; Di Yu; Zhanguo Li
Journal:  Nat Med       Date:  2016-08-08       Impact factor: 53.440

Review 8.  Restoring regulation - IL-2 therapy in systemic lupus erythematosus.

Authors:  Jens Y Humrich; Gabriela Riemekasten
Journal:  Expert Rev Clin Immunol       Date:  2016-06-23       Impact factor: 4.473
  8 in total
  7 in total

1.  The rise of IL-2 therapy - a picture beyond Treg cells.

Authors:  Zhanguo Li; Jing He; Di Yu
Journal:  Nat Rev Rheumatol       Date:  2017-05-11       Impact factor: 20.543

2.  Low-dose IL-2 therapy - a complex scenario that remains to be further explored.

Authors:  Jens Y Humrich; Gabriela Riemekasten
Journal:  Nat Rev Rheumatol       Date:  2017-05-11       Impact factor: 20.543

3.  Bioinformatics analysis of differentially expressed gene profiles associated with systemic lupus erythematosus.

Authors:  Chengjiang Wu; Yangjing Zhao; Yu Lin; Xinxin Yang; Meina Yan; Yujiao Min; Zihui Pan; Sheng Xia; Qixiang Shao
Journal:  Mol Med Rep       Date:  2017-12-18       Impact factor: 2.952

4.  IL-2 Therapy Diminishes Renal Inflammation and the Activity of Kidney-Infiltrating CD4+ T Cells in Murine Lupus Nephritis.

Authors:  Angelika Rose; Caroline von Spee-Mayer; Lutz Kloke; Kaiyin Wu; Anja Kühl; Philipp Enghard; Gerd-Rüdiger Burmester; Gabriela Riemekasten; Jens Y Humrich
Journal:  Cells       Date:  2019-10-11       Impact factor: 6.600

Review 5.  Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases.

Authors:  Hanna Graßhoff; Sara Comdühr; Luisa R Monne; Antje Müller; Peter Lamprecht; Gabriela Riemekasten; Jens Y Humrich
Journal:  Front Immunol       Date:  2021-04-01       Impact factor: 7.561

6.  Increased sIL-2Rα leads to obstruction of IL-2 biological function and Treg cells differentiation in SLE patients via binding to IL-2.

Authors:  Dan Long; Shujiao Yu; Lu Zhang; Yang Guo; Shumin Xu; Yuting Rao; Zikun Huang; Qing Luo; Junming Li
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786

7.  Site-Mutation of Hydrophobic Core Residues Synchronically Poise Super Interleukin 2 for Signaling: Identifying Distant Structural Effects through Affordable Computations.

Authors:  Longcan Mei; Yanping Zhou; Lizhe Zhu; Changlin Liu; Zhuo Wu; Fangkui Wang; Gefei Hao; Di Yu; Hong Yuan; Yanfang Cui
Journal:  Int J Mol Sci       Date:  2018-03-20       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.